EMBC 📈 Embecta - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29082K1051
EMBC: Diabetes, Needles, Syringes, Injection Devices, Digital Applications
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. Web URL: https://www.embecta.com
Additional Sources for EMBC Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EMBC Stock Overview
| Market Cap in USD | 1,110m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Health Care Supplies |
| IPO / Inception | 2022-04-01 |
EMBC Stock Ratings
| Growth 5y | -67.3% |
| Fundamental | -54.5% |
| Dividend | 48.0% |
| Rel. Strength Industry | 253 |
| Analysts | 3.5/5 |
| Fair Price Momentum | 19.31 USD |
| Fair Price DCF | 6.14 USD |
EMBC Dividends
| Dividend Yield 12m | 2.97% |
| Yield on Cost 5y | 1.17% |
| Annual Growth 5y | 41.42% |
| Payout Consistency | 100.0% |
EMBC Growth Ratios
| Growth Correlation 3m | 73.5% |
| Growth Correlation 12m | 17% |
| Growth Correlation 5y | -81.8% |
| CAGR 5y | -28.61% |
| CAGR/Mean DD 5y | -0.55 |
| Sharpe Ratio 12m | 0.44 |
| Alpha | -3.57 |
| Beta | 0.63 |
| Volatility | 49.55% |
| Current Volume | 1407.3k |
| Average Volume 20d | 560.6k |
What is the price of EMBC stocks?
As of December 22, 2024, the stock is trading at USD 20.23 with a total of 1,407,343 shares traded.
Over the past week, the price has changed by +3.69%, over one month by +49.77%, over three months by +30.58% and over the past year by +18.17%.
As of December 22, 2024, the stock is trading at USD 20.23 with a total of 1,407,343 shares traded.
Over the past week, the price has changed by +3.69%, over one month by +49.77%, over three months by +30.58% and over the past year by +18.17%.
Is Embecta a good stock to buy?
No, based on ValueRay Fundamental Analyses, Embecta (NASDAQ:EMBC) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -54.46 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EMBC as of December 2024 is 19.31. This means that EMBC is currently overvalued and has a potential downside of -4.55%.
No, based on ValueRay Fundamental Analyses, Embecta (NASDAQ:EMBC) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -54.46 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EMBC as of December 2024 is 19.31. This means that EMBC is currently overvalued and has a potential downside of -4.55%.
Is EMBC a buy, sell or hold?
Embecta has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold EMBC.
Embecta has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold EMBC.
- Strong Buy: 2
- Buy: 0
- Hold: 3
- Sell: 1
- Strong Sell: 0
What are the forecast for EMBC stock price target?
According to ValueRays Forecast Model, EMBC Embecta will be worth about 20.9 in December 2025. The stock is currently trading at 20.23. This means that the stock has a potential upside of +3.16%.
According to ValueRays Forecast Model, EMBC Embecta will be worth about 20.9 in December 2025. The stock is currently trading at 20.23. This means that the stock has a potential upside of +3.16%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 21.1 | 4.1% |
| Analysts Target Price | 16 | -20.9% |
| ValueRay Target Price | 20.9 | 3.2% |